Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and lowers the price t

Stockholm, July 1st, 2026 – Virtune today announces the completion of the rebalancing for the Virtun

Chemours (CC) was a big mover last session on higher-than-average trading volume. The latest trend i

JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and raises the pr

Morgan Stanley analyst Vincent Andrews maintains Chemours (NYSE:CC) with a Equal-Weight and raise

Analysts changed outlook on top names, RBC raised CC price target, DA Davidson lowered MSA target, O

Wall Street has rarely been louder with bubble warnings on the AI trade after the parabolic moves we

RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and raises th

Memory is yesterday's trade. Liquid cooling is the next AI backlog story — Carrier orders up 500

Full Year 2026 Outlook The Company continues to expect 2026 Net Sales to grow in the range of 3% to

Second Quarter 2026 Outlook In the second quarter, the Company anticipates consolidated Net Sales to

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and raises the

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and raises the

Dow Jones up 150 pts, Citi Trends $CTRN up 20.8% on strong earnings, other big gainers include Getty

BMO warns Middle East conflict is the biggest oil market event in decades. See how supply risks are

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and raises the price t

Goldman Sachs analyst Duffy Fischer maintains Chemours (NYSE:CC) with a Neutral and raises the pr

Successful qualification of Opteon™ fluid in 2CRSi server sparks broader collaboration to drive inno

BMO Capital analyst John McNulty maintains Chemours (NYSE:CC) with a Outperform and lowers the pr

JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and raises the pr

Morgan Stanley analyst Vincent Andrews maintains Chemours (NYSE:CC) with a Equal-Weight and raise

Chemours (NYSE:CC) reported quarterly earnings of $0.05 per share which missed the analyst consensus

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and raises the

The Chemours Company ("Chemours" or "the Company") (NYSE:CC), a global chemistry com

JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and lowers the pr

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the

RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and lowers th

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and lowers the price t

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and raises the price t

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and raises the

Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could

On August 29, 2025, Dawn Farrell, Chair of the Board of Directors (the "Board") of The Chemo

DuPont agreed to sell its Aramids business, including Kevlar and Nomex brands, to Arclin for $1.8B.

Chemours Company reports Q4 net sales of $1.359 billion, in line with consensus. Adjusted EBITDA imp